These data suggest that the treatment with anti-CD29 antibody on tumor-bearing animals inhibits tumor growth by promoting T-cell-mediated immunity, as anti-CD29 administration did not exert anti-tumor effects in the absence of B and T cells (Figure 6E). This evidence concerns the gene ITGB1 and neoplasm.